Title: An analysis on efficacy and safety of combined bicyclol and magnesium isoglycyrrhizinate in treatment of liver cirrhosis
Abstract: Objective To explore the efficacy and safety of combined bicyclol and magnesium isoglycyrrhizinate in the treatment of liver cirrhosis.Methods A total of 120 patients who had been suffering from decompensated cirrhosis and admitted to our hospital were selected and randomly divided into a bicyclol group,a magnesium isoglycyrrhizinate group and a combination group (n=40,respectively).On the basis of routine treatment,the bicyclol group took bicyclol tablets orally,the magnesium isoglycyrrhizinate group was treated with magnesium isoglycyrrhizinate through intravenous drip,and the combination group was treated with both bicyclol tablets and magnesium isoglycyrrhizinate injection.Two weeks later,the changes in the indicators of liver function and liver fibrosis as well as clinical efficacy before and after the treatment were compared among the three groups.Results After the treatment,the levels of alanine aminotransferase (ALT),aspartate aminotransferase (AST),serum total bilirubin (TB),laminin (LN) and hyaluronic acid (HA) in the combination group were obviously lower than those in another two groups (P < 0.05),and the total effective rate of clinical treatment was also obviously higher than that in the other two groups (95.00% vs 67.50% and 70.00%) (P < 0.05);during the treatment,there were no significant differences in adverse reactions among three groups (P > 0.05).Conclusion The combined bicyclol and magnesium isoglycyrrhizinate has significant effect in the treatment of decompensated cirrhosis and can help safely improve the liver functions and liver fibrosis of patients,with better effect than either bicyclol or magnesium isoglycyrrhizinate when used alone.
Publication Year: 2018
Publication Date: 2018-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot